Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

British Journal of Cancer

Volumn 96, Issue 12, 2007, Pages 1828-1833

  Mercadante, S ^a,b   Villari, P ^a   Ferrera, P ^a   Casuccio, A ^b   Mangione, S ^b   Intravaia, G ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Breakthrough pain; Cancer pain; Intravenous morphine; Opioids; OTFC

Indexed keywords

FENTANYL CITRATE; MORPHINE; OPIATE;

ADULT; AGED; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TITRIMETRY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FEMALE; FENTANYL; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN;

EID: 34250339548     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603811     Document Type: Article

References (16)

1. Christie J, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, Portenoy RK (1998) Dose- titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16: 3238-3245
2. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 91: 123-130
3. Farrar J, Cleary J, Rauck R, Busch M, Nordbrock E (1998) Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 90: 611-616
4. Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94: 149-158
5. Fine PG (2005) The evolving and important role of anesthesiology in palliative care. Anesth Analg 100: 183-188
6. Hagen NA, Fisher K, Victorino C, Farrar JT (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10: 47-55
7. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V, Expert Working Group of the Research Network of the European Association for Palliative Care (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587-593
8. Hanks GW, Nugent M, Higgs CMB, Busch MA (2004) Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, muticentre, dose-titration and long-term use study. Palliat Med 18: 698-704
9. Lichtor JL, Sevarino FB, Joshi GP, Busch MA, Nordbrock E, Ginsberg B (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 89: 732-738
10. Lu JK, Bailey PL (2003) Dose-related respiratory pharmacology of oral transmucosal fentanyl citrate (OTFC) versus intravenous morphine: a randomized, double-blind, double-dummy study. Anesthesiology 99: A967
11. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S (2005) Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 30: 485-491
12. Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A (2004) Safety and effectiveness of intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 27: 352-359
13. Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A (2006) Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 32: 175-179
14. Mercadante S, Villari P, Ferrera P (2003) A model of acute symptom control unit: pain relief and palliative care unit of La Maddalena Cancer center. Support Care Cancer 11: 114-119
15. Portenoy RK, Payne D, Jacobson P (1999a) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129-134
16. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M (1999b) Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303-312